P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial

被引：0

作者：

Genovese, Mark C. ^{[1
]}

Lertratanakul, Apinya ^{[2
]}

Anderson, Jaclyn ^{[2
]}

Papp, Kim ^{[3
]}

Tillett, William ^{[4
]}

van den Bosch, Filip ^{[5
]}

Tsuji, Shigeyoshi ^{[6
]}

Dokoupilova, Eva ^{[7
]}

Keiserman, Mauro ^{[8
]}

Wang, Xin ^{[2
]}

Zhong, Sheng ^{[2
]}

Zueger, Patrick ^{[2
]}

Pangan, Aileen ^{[2
]}

Mease, Philip ^{[9
,10
]}

机构：

[1] Stanford Univ, Sch Med, Dept Immunol & Rheumatol, Palo Alto, CA USA

[2] AbbVie Inc, Med, N Chicago, IL USA

[3] Papp Clin Res & Prob Med Res, Waterloo, ON, Canada

[4] Royal Natl Hosp Rheumat Dis, Rheumatol, Bath, Avon, England

[5] Ghent Univ Hosp, Dept Internal Med, Ghent, Belgium

[6] Osaka Minami Med Ctr, Dept Orthopaed Rheumatol, Osaka, Japan

[7] Uherske Hradiste & Univ Vet & Pharmaceut Sci, Med Plus, Brno, Czech Republic

[8] Pontificia Univ Catolica, Sch Med, Porto Alegre, RS, Brazil

[9] Swedish Med Ctr, Dept Rheumatol, Seattle, WA USA

[10] Univ Washington, Seattle, WA 98195 USA

来源：

RHEUMATOLOGY | 2021年 / 60卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：1

共 50 条

[1] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSA AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMISED CONTROLLED PHASE III TRIAL
Genovese, Mark C.
Lertratanakul, Apinya
Anderson, Jaclyn
Papp, Kim
Tillett, William
van den Bosch, Filip
Tsuji, Shigeyoshi
Dokoupilova, Eva
Keiserman, Mauro
Wang, Xin
Zhong, Sheng
Zueger, Patrick
Pangan, Aileen
Mease, Philip
RHEUMATOLOGY, 2021, 60 : 90 - 90
[2] EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSA AND INADEQUATE RESPONSE TO NON-BIOLOGIC DMARDS (SELECT-PSA-1): A DOUBLE-BLIND, RANDOMISED CONTROLLED PHASE III TRIAL
McInnes, Iain
Anderson, Jaclyn
Magrey, Marina
Merola, Joseph F.
Liu, Yi
Kishimoto, Mitsumasa
Jeka, Slawomir
Pacheco-Tena, Cesar
Wang, Xin
Chen, Liang
Zueger, Patrick
Pangan, Aileen
Behrens, Frank
RHEUMATOLOGY, 2021, 60 : 92 - 92
[3] P173 Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial
McInnes, Iain
Anderson, Jaclyn
Magrey, Marina
Merola, Joseph F.
Liu, Yi
Kishimoto, Mitsumasa
Jeka, Slawomir
Pacheco-Tena, Cesar
Wang, Xin
Chen, Liang
Zueger, Patrick
Pangan, Aileen
Behrens, Frank
RHEUMATOLOGY, 2021, 60
[4] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Genovese, M. C.
Lertratanakul, A.
Anderson, J.
Papp, K.
Tillett, W.
Van den Bosch, F.
Tsuji, S.
Dokoupilova, E.
Keiserman, M.
Wang, X.
Zhong, S.
Zueger, P.
Pangan, A.
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 139 - 139
[5] Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
Coates, Laura
Bakewell, Catherine
Khraishi, Majed
Chen, Shirley
Gao, Tianming
Setty, Arathi
Jones, Heather
Ciecinski, Sandra
Mysler, Eduardo
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2793 - 2795
[6] EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Mcinnes, I.
Anderson, J.
Magrey, M.
Merola, J. F.
Liu, Y.
Kishimoto, M.
Jeka, S.
Tena, C. F. Pacheco
Wang, X.
Chen, L.
Zueger, P.
Pangan, A.
Behrens, F.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 12 - 13
[7] Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
van der Heijde, Desiree
Song, In-Ho
Pangan, Aileen L.
Deodhar, Atul
van den Bosch, Filip
Maksymowych, Walter P.
Kim, Tae-Hwan
Kishimoto, Mitsumasa
Everding, Andrea
Sui, Yunxia
Wang, Xin
Chu, Alvina D.
Sieper, Joachim
LANCET, 2019, 394 (10214): : 2108 - 2117
[8] Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Genovese, Mark
Lertratanakul, Apinya
Anderson, Jaclyn K.
Papp, Kim
Tillett, William
Van den Bosch, Filip
Tsuji, Shigeyoshi
Dokoupilova, Eva
Keiserman, Mauro
Wang, Xin
Zhong, Sheng
Zueger, Patrick
Pangan, Aileen
Mease, Philip
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[9] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
Smolen, J. S.
Cohen, S.
Emery, P.
Rigby, W.
Tanaka, Y.
Zhang, Y.
Friedman, A.
Othman, A. A.
Camp, H. S.
Pangan, A. L.
RHEUMATOLOGY, 2019, 58
[10] UPADACITINIB AS MONOTHERAPY: A PHASE 3 RANDOMISED CONTROLLED DOUBLE-BLIND STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE
Smolen, J.
Cohen, S.
Emery, P.
Rigby, W.
Tanaka, Y.
Zhang, Y.
Friedman, A.
Othman, A.
Camp, H.
Pangan, A.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 67 - 68

← 1 2 3 4 5 →